50463-48-4

Usage

Uses

Used in Pharmaceutical Industry:
3-[4-(Benzyloxy)phenyl]propionic acid is used as an anti-inflammatory and analgesic agent for the treatment of various conditions characterized by inflammation and pain. Its application is primarily due to its ability to inhibit prostaglandin production, thereby reducing inflammation and alleviating pain.
Used in Orthopedic Applications:
In the orthopedic field, 3-[4-(Benzyloxy)phenyl]propionic acid is used as a therapeutic agent for the management of arthritis and other joint-related conditions. Its anti-inflammatory and analgesic properties help in reducing joint inflammation and associated pain, improving the quality of life for patients suffering from such conditions.
Used in Gynecological Applications:
3-[4-(Benzyloxy)phenyl]propionic acid is used as a treatment for menstrual cramps, leveraging its analgesic and anti-inflammatory properties to alleviate the pain and discomfort associated with menstruation.
Used in Pain Management:
For minor aches and pains, 3-[4-(Benzyloxy)phenyl]propionic acid is used as an over-the-counter pain reliever, providing temporary relief from various types of pain, such as headaches, muscle aches, and back pain.

InChI:InChI=1/C16H16O3/c17-16(18)11-8-13-6-9-15(10-7-13)19-12-14-4-2-1-3-5-14/h1-7,9-10H,8,11-12H2,(H,17,18)

Upstream product

• 501-97-3 4-hydroxyphenylpropionic acid 
• 100-39-0 benzyl bromide 
• 5597-50-2 3-(4-hydroxyphenyl)propionic acid methyl ester 
• 100-44-7 benzyl chloride 
• 24807-40-7 methyl 3-(4-benzyloxyphenyl)propanoate 
• 58608-97-2 3-(4-benzyloxyphenyl)propionic acid benzyl ester 
• 100-51-6 benzyl alcohol 
• 7400-08-0 p-Coumaric Acid 
• 836-43-1 4-benzyloxybenzyl alcohol 
• 84184-50-9 diethyl 2-(4-benzyloxybenzyl)malonate 
• 836-42-0 4-benzyloxybenzyl chloride 
• 7400-08-0 para-coumaric acid 

Downstream Products

• 142272-42-2 4-Benzyloxy-3'-oxodecylbenzene 
• 131946-62-8 N-<2-(3,4-dibenzyloxyphenyl)ethyl>-3-(4-benzyloxyphenyl)propionamide 
• 61440-45-7 3-[4-(benzyloxy)phenyl]propan-1-ol 
• 24807-40-7 methyl 3-(4-benzyloxyphenyl)propanoate 
• 477284-08-5 3-(4-Benzyloxy-phenyl)-propionic acid (S)-1-[4-(toluene-4-sulfonyloxy)-phenyl]-but-3-enyl ester 
• 477284-12-1 C₂₆H₂₅ClO₃ 
• 945493-32-3 methyl (S)-2-[N-allyl-3-(4-benzyloxyphenyl)propanamido]-5-(triisopropylsilyloxy)pentanoate 
• 945492-87-5 (S)-2-[N-allyl-3-(4-benzyloxyphenyl)propanamido]-5-(triisopropylsilyloxy)pentanoic acid 
• 945492-93-3 (2R,S)-2-[N-allyl-3-(4-benzyloxyphenyl)propanamido]-N-[(2S)-1-(N-allyl-o-nitrophenylsulfonamido)-5-triisopropylsilyloxypentan-2-yl]-5-triisopropylsilyloxypentanamide 
• 945492-94-4 (2R,S)-2-[N-allyl-3-(4-benzyloxyphenyl)propanamido]-N-[(2R)-1-(N-allyl-o-nitrophenylsulfonamido)-5-triisopropylsilyloxypentan-2-yl]-5-triisopropylsilyloxypentanamide 
• 945492-99-9 (2S,5S,6E)-2,5-bis[3-(triisopropylsilyloxy)propyl]-1-[3-(4-benzyloxyphenyl)propionyl]-7-(o-nitrobenzenesulfonyl)-1,4,7-triazacycloundec-9-en-3-one 
• 945493-00-5 (2R,5S,6E)-2,5-bis[3-(triisopropylsilyloxy)propyl]-1-[3-(4-benzyloxyphenyl)propionyl]-7-(o-nitrobenzenesulfonyl)-1,4,7-triazacycloundec-9-en-3-one 
• 945493-02-7 (2R,5R,6E)-2,5-bis[3-(triisopropylsilyloxy)propyl]-1-[3-(4-benzyloxyphenyl)propionyl]-7-(o-nitrobenzenesulfonyl)-1,4,7-triazacycloundec-9-en-3-one 
• 945493-01-6 (2S,5R,6E)-2,5-bis[3-(triisopropylsilyloxy)propyl]-1-[3-(4-benzyloxyphenyl)propionyl]-7-(o-nitrobenzenesulfonyl)-1,4,7-triazacycloundec-9-en-3-one 

Relevant academic research and scientific papers

The total syntheses of JBIR-94 and two synthetic analogs and their cytotoxicities against A549 (CCL-185) human small lung cancer cells

We here disclose the total syntheses of the natural polyphenol JBIR-94 and two nonnatural analogs, whose structures are of interest for their bioactivity potential as radical scavengers. Although we initially attempted this by dually acylating both of putrecine's amine nitrogens in a single pot, our endeavors with this method (which has been successfully reported by other groups) proved ineffectual. We accordingly opted for the lengthier approach of acylating each amine individually, which gratuitously prevailed and also aligns with separate literature precedent. Moreover, we here share our analysis of these target compounds’ cytotoxicities and IC50 values against A549 (CCL-185) human small lung cancer cells.

Computer-Aided Fragment Growing Strategies to Design Dual Inhibitors of Soluble Epoxide Hydrolase and LTA4 Hydrolase

Multitarget ligands are interesting candidates for drug discovery and development due to improved safety and efficacy. However, rational design and optimization of multitarget ligands is tedious because affinity optimization for two or more targets has to be performed simultaneously. In this study, we demonstrate that, given a molecular fragment, which binds to two targets of interest, computer-aided fragment growing can be applied to optimize compound potency, relying on either ligand- or structure-derived information. This methodology is applied to the design of dual inhibitors of soluble epoxide hydrolase and leukotriene A4 hydrolase.

Benzoic hydroxamate-based iron complexes as model compounds for humic substances: Synthesis, characterization and algal growth experiments

A series of monomeric and dimeric FeIII complexes bearing benzoic hydroxamates as O,O-chelates has been prepared and characterized by elemental analysis, IR spectroscopy, UV-Vis spectroscopy, electrospray ionization mass spectrometry (ESI-MS), cyclic voltammetry, EPR spectroscopy and for some examples by X-ray diffraction analysis. The stability of the synthesized complexes in pure water and seawater was monitored over 24 h by means of UV-Vis spectrometry. The ability to release iron from the synthesized model complexes has been investigated with algae growth experiments.

COMPOUND EXHIBITING REGULATORY ACTIVITY ON LYSOPHOSPHATIDYLSERINE RECEPTOR FUNCTION

The object of the present invention is to provide a compound having a lysophosphatidylserine receptor function modulation activity or a salt thereof. A compound having a lysophosphatidylserine receptor function modulation activity or a salt thereof, or a pharmaceutical composition or a lysophosphatidylserine receptor function moderator containing such compound or salt is provided by the present invention.

POLYMERIZABLE CHIRAL COMPOUND

The present invention refers to, a strong HTP and a, a lower melting point as chiral compounds having a diffusion barrier it is an object to provide an 1/10 time as large as that of. Said liquid crystal aberration correcting element, general formula (I) Polymerizable chiral reagent represented by compound. Subject to the compounds of the invention herein having a melting and low HTP, since a color compound melting portion of the electron emitting material paste excellent drives liquid crystal composition, is useful as a components. Furthermore, as a component compound polymerizable chiral reagent of the invention herein a polymerizable liquid crystal composition, to produce large-sized content of compound polymerizable chiral reagent of the insertion part and the holder and having excellent optical characteristics and operating method of anisotropic body group represented by the formula 1.. A optically anisotropic product, of the invention herein, the deflecting plates, retardation plate and the like useful.

Synthesis of the alkaloid tyroscherin by an aldol/Curtius strategy

The alkaloid tyroscherin (2), which contains a vicinal anti-amino alcohol subunit was prepared from 4-hydroxyphenylpropionic acid (5) and meso-diol 9. After desymmetrization of diol 9 and suitable protecting group manipulations, one terminus was extended via a Claisen rearrangement giving rise to enoate ent-15. The missing carbon on the other end could be incorporated using MeMgCl/CuBr·SMe2 leading eventually to aldehyde ent-22. The acylated oxazolidinone 32 derived from acid 5 and aldehyde ent-22 were combined in an aldol reaction. A subsequent Curtius rearrangement on the carboxylic group furnished the amino function of tyroscherin (2). In a proof of concept study the same strategy was used to prepare tyroscherin analog 28.

Structure-activity study of dihydrocinnamic acids and discovery of the potent FFA1 (GPR40) agonist TUG-469

The free fatty acid 1 receptor (FFA1 or GPR40), which is highly expressed on pancreatic β-cells and amplifies glucose-stimulated insulin secretion, has emerged as an attractive target for the treatment of type 2 diabetes. Several FFA1 agonists containing the para-substituted dihydrocinnamic acid moiety are known. We here present a structure-activity relationship study of this compound family suggesting that the central methyleneoxy linker is preferable for the smaller compounds, whereas the central methyleneamine linker gives higher potency to the larger compounds. The study resulted in the discovery of the potent and selective full FFA1 agonist TUG-469 (29).

NOVEL POLYSPIRANE COMPOUNDS, APPLICATION THEREOF IN THE TREATMENT OF MALARIA OR TOXOPLASMOSIS AND METHOD FOR PREPARING SAME

Novel polyspirane compounds used in the treatment of diseases involving parasites that belong to the phylum of apicomplexae, and a method for preparing the same.

Synthesis of the pyoverdin chromophore by a biomimetic oxidative cyclization

The fluorescent dihydropyrimido[1,2-a]quinoline chromophore of the pyoverdin siderophores has been synthesized by a biomimetic oxidative cyclization using an iodine (III) reagent, followed by elimination and dehydrogenation.

TETRACYCLIC INHIBITORS OF FATTY ACID AMIDE HYDROLASE

Certain tetracyclic compounds are described, which may be used in pharmaceutical compositions and methods for treating disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis).